Chemoproteomics studies have uncovered multiple potential kinase drug targets in the Plasmodium protozoan that causes malaria, and subsequent screening of approved kinase inhibitor drugs has now thrown up several hits with lethal activity at different stages of the complex life cycle of the parasite. Researchers at the University of Cape Town, South Africa, working with scientists at Glaxosmithkline plc, describe the activity in Plasmodium of one of these kinase inhibitors, the cancer drug sapanisertib, in a paper appearing in Science Translational Medicine, Oct. 19, 2022.